SIGLA SCIENCES introduces our Foresight White Paper series offering strategic insights into the major technology and data trends impacting life sciences decisionmakers.
The rapid evolution of Artificial Intelligence (AI) and Large Language Models (LLMs) is already disrupting the life sciences sector. From accelerating drug discovery to enhancing patient engagement, the application of AI technologies presents numerous opportunities for innovation and improved efficiency across the product lifecycle.
This executive white paper elucidates a structured Dual-Axis Framework to categorize and explore the various applications of AI and LLMs within the biopharmaceutical and life sciences domain, empowering discussion and decision making around how these tools can be evaluated, developed, and deployed.
What can AI do for the life sciences industry? What is it already doing? These technologies can expedite the research & discovery phase, streamline regulatory submissions, enhance market access strategies, and foster a more patient-centric approach in post-market engagement. However, AI deployment is not without challenges, ethical quandaries, and regulatory constraints. Leaders should be prepared.
